New code of medical ethics: 10 Key changes in pharma doctor interactions

Published On 2023-08-18 09:59 GMT   |   Update On 2023-08-18 09:59 GMT

The new code of conduct is out, and have ordered a major crackdown on the unethical practices of some members of the medical fraternity on taking freebies and benefits from pharmaceuticals, medical devices and allied healthcare companies in lieu of indirect promotion of their products, including prescriptions. While the major feature of the guidelines has been a blanket direction to doctors...

Login or Register to read the full article

The new code of conduct is out, and have ordered a major crackdown on the unethical practices of some members of the medical fraternity on taking freebies and benefits from pharmaceuticals, medical devices and allied healthcare companies in lieu of indirect promotion of their products, including prescriptions. While the major feature of the guidelines has been a blanket direction to doctors to prescribe generic names, there has been a separate clause dedicated to engagement with pharma, commercial healthcare establishments, medical device companies, or corporate hospitals.

Section 35 of the National Medical Commission Registered Medical Practitioner RMP (Professional Conduct) Regulations 2023 state

RMPs and their families must not receive any gifts, travel facilities, hospitality, cash or monetary grants, consultancy fee or honorariums, or access to entertainment or recreation from pharmaceutical companies or their representatives, commercial healthcare establishments, medical device companies, or corporate hospitals under any pretext. However, this does not include salaries and benefits that RMPs may receive as employees of these organizations. Also, RMPs should not be involved in any third-party educational activity like CPD, seminar, workshop, symposia, conference, etc., which involves direct or indirect sponsorships from pharmaceutical companies or the allied health sector. RMP should be aware of the conflict-of-interest situations that may arise. The nature of these relationships should be in the public domain such as clinical drug trials and should not be in contravention of any law, rule, or regulation in force. RMP himself or as part of any society, organization, association, trust, etc. make regarding the relationship with the pharmaceutical and allied health sector industry clear and transparent open to scrutiny. (L3)

For more details, check out the link given below:

Pharma-Doctor Interactions: What Has Changed In The New Code Of Medical Ethics? 10 Important Takeaways

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News